What kilab does

KILAB is an Argentine pharmaceutical laboratory headquartered in Buenos Aires that manufactures and distributes medicinal specialties for the domestic hospital channel. The company operates two manufacturing facilities in Buenos Aires: Planta Pompeya, a three-floor plant equipped with state-of-the-art equipment for producing solid dosage forms (capsules and tablets), and Planta Liniers, acquired from LIA (Abbott Argentina) in 2021, dedicated to specialized production of cephalosporin and beta-lactam antibiotics. KILAB's proprietary portfolio comprises approximately 30 pharmaceutical products spanning multiple therapeutic categories, including cephalosporin and carbapenem antibiotics, hormonal therapies (anastrozole, bicalutamide, cyproterone), bronchodilators (salbutamol, ipratropium bromide), NSAIDs (diclofenac), PPIs (omeprazole), antivirals (acyclovir), benzodiazepines (clonazepam), and a CBD-based topical cream developed through a research collaboration with Universidad de Hurlingham.

The company's operations are grounded in strict pharmaceutical manufacturing standards (GMP) and specialized process know-how — particularly for segregated beta-lactam and cephalosporin production lines at the Liniers facility. In addition to proprietary manufacturing, KILAB offers third-party manufacturing services (tercerismo) under four flexible engagement models: full product completion, contract (toll) manufacturing, quality control and direction services, and joint associative development. The company's R&D function develops new proprietary products in-house and collaborates externally with academic institutions.

KILAB operates a sales-led, B2B distribution model targeting Argentine hospitals and pharmaceutical companies. Products are sold exclusively for hospital use in bulk quantities (e.g., boxes of 25 to 504 units depending on product) via a quotation-based online procurement system with account registration. The company serves approximately 130 clients and is privately held with no disclosed institutional investors or funding rounds. The firm employs around 72 professionals across its two plants and headquarters, with revenue model split between proprietary product sales and third-party manufacturing services.

Name

kilab

Legal name

KILAB

Website

https://laboratoriokilab.com.ar

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

KILAB is an Argentine pharmaceutical laboratory operating two GMP manufacturing plants in Buenos Aires that produce ~30 proprietary hospital-exclusive medications (antibiotics, hormonal therapies, bronchodilators) and offer third-party manufacturing services to ~130 hospital and pharma clients.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Third-party Pharmaceutical Manufacturing: Complete manufacturing services for pharmaceutical products including 100% finished product production, contract manufacturing, quality control and direction services, and joint development models
2. Proprietary Product Sales: Sale of 30 proprietary pharmaceutical products including antibiotics, hormonal therapies, bronchodilators, and other medicinal specialties

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

KILAB is an Argentine pharmaceutical laboratory that develops, manufactures, and sells approximately 30 hospital-exclusive pharmaceutical products (antibiotics, hormonal therapies, bronchodilators, anti-inflammatory drugs, antivirals, and a CBD topical cream) and provides complementary third-party contract manufacturing, quality control testing, and product development services from its Pompeya and Liniers plants in Buenos Aires.

Product overview

KILAB is a pharmaceutical laboratory in Argentina operating under strict pharmaceutical manufacturing standards. The company offers a diverse portfolio of approximately 30 pharmaceutical products across multiple therapeutic categories including antibiotics (cephalosporins, penicillins, carbapenems, rifampicin), hormonal therapies (anastrozol, bicalutamida, ciproterona), bronchodilators (salbutamol, ipratropio bromide), anticonvulsants (clonazepam), anti-inflammatory drugs (diclofenac), antivirals (aciclovir), and antacids (omeprazol). The CBD Cream represents an innovative product developed through research collaboration with Universidad de Hurlingham. Beyond product manufacturing, KILAB provides comprehensive third-party manufacturing services, quality control testing, and product development services. The company operates two manufacturing facilities: Planta Pompeya for solids, capsules, and tablets; and Planta Liniers (acquired from Abbott Argentina in 2021) dedicated to cephalosporin and beta-lactam antibiotic production.

Differentiator

Problem solved

Functional benefit

Products and services

• Aciclovir Antiviral medication for treating herpes infections, part of KILAB's hospital pharmaceutical portfolio.
• Akitropio (Ipratropio Bromuro) Bronchodilator medication for treating respiratory conditions, part of KILAB's hospital pharmaceutical portfolio.
• Ampicilina + Sulbactam Antibiotic combination product within the penicillins category for treating bacterial infections, part of KILAB's hospital pharmaceutical portfolio.
• Anastrozol Hormone therapy medication used in breast cancer treatment, part of KILAB's hospital pharmaceutical portfolio.
• Bicalutamida Antiandrogen medication used in hormone therapy for prostate cancer, part of KILAB's hospital pharmaceutical portfolio.
• CBD Cream (Cannabidiol) Topical cream containing CBD developed in partnership with Universidad de Hurlingham, highlighting anti-inflammatory and antibiotic properties.
• Cefalotina First-generation cephalosporin antibiotic for treating bacterial infections, manufactured at the Liniers plant.
• Cefazolina First-generation cephalosporin antibiotic used for surgical prophylaxis and treatment of infections, manufactured at the Liniers plant.
• Cefepime Fourth-generation cephalosporin antibiotic with extended spectrum activity, manufactured at the Liniers plant.
• Cefotaxima Third-generation cephalosporin antibiotic for treating serious infections, manufactured at the Liniers plant.
• Ceftazidima Third-generation cephalosporin antibiotic particularly effective against Pseudomonas aeruginosa, manufactured at the Liniers plant.
• Ceftriaxona Third-generation cephalosporin antibiotic widely used for various bacterial infections, manufactured at the Liniers plant.
• Ciproterona Antiandrogen medication used in hormonal therapy, presented as 50mg tablets for hospital use.
• Clonazepam Benzodiazepine with anxiolytic and anticonvulsant properties, presented as 2.0mg tablets for hospital use (500 tablets per box).
• Diclofenac 100 AP Anti-inflammatory, analgesic, and NSAID with prolonged-release microgranules in capsules, presented as 504 capsules per box for hospital use.
• Imipenem + Cilastatina Carbapenem antibiotic combination for treating severe nosocomial infections, manufactured at the Liniers plant.
• Meropenem Carbapenem antibiotic available in 500mg and 1000mg injectable formulations, presented as 50 vials per box for hospital use.
• Omeprazol Proton pump inhibitor that reduces stomach acid production, available in 20mg capsules (504 per box) and 40mg injectable for hospital use.
• Penicilina Penicillin antibiotic available in 3,000,000 IU injectable formulation for hospital use.
• Piperacilina + Tazobactam Extended-spectrum penicillin antibiotic combined with beta-lactamase inhibitor for treating hospital-acquired infections.
• Rifampicina Antituberculous antibiotic available in multiple formulations including 300mg capsules (8 per box), 2% oral suspension, and 600mg injectable, presented as hospital boxes.
• Salbutamol Selective beta-2 adrenergic agonist bronchodilator for treating obstructive respiratory conditions, available as inhaler with 100 unit hospital boxes.
• Contract Manufacturing Services (Tercerismo) Third-party manufacturing services including complete product manufacturing, toll manufacturing (fasón), quality control and direction, and joint associative manufacturing models with flexible working modalities for pharmaceutical companies.
• Quality Control Services Quality control services for evaluating materials and finished products for third parties.
• Product Development Services Development area that innovates with new proprietary products and collaborates on external projects.

Quantifiable outcome

• 130 pharmaceutical clients served
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Universidad de HurlinghamcoreStrategic or Co-development Partner · 1 January 2023Research collaboration in 2023 focused on CBD studies, highlighting anti-inflammatory and antibiotic properties. Research expanded to other therapeutic areas.
• LIA (Abbott Argentina)coreOthers · 1 January 2021KILAB acquired the pharmaceutical plant located in Liniers from LIA (Abbott Argentina) in 2021. The plant specializes in cephalosporin and beta-lactam antibiotic production.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Eurofarma: Largest Brazilian-owned pharmaceutical company with significant operations across Latin America in branded generics and hospital products. Comparable as a larger regional pharma expanding in Argentina and the broader Southern Cone market.

Direct peers

• Laboratorios Bernabó: Mid-sized Argentine pharmaceutical company with a hospital-focused portfolio and CDMO capabilities. Comparable based on similar GMP-certified manufacturing, Argentine market focus, and contract manufacturing services overlap.
• Laboratorios Bagó: Major Argentine pharmaceutical laboratory with branded generics, hospital products, and contract manufacturing capabilities. Comparable by virtue of scale, therapeutic breadth, and Argentina-focused B2B hospital sales similar to KILAB.
• Grupo Roemmers: Argentina's largest domestic pharmaceutical manufacturer with a broad branded generics and specialty portfolio across antibiotics, hormones, and hospital products. Directly comparable to KILAB as a GMP-certified Argentine manufacturer serving hospitals with a similar therapeutic mix.
• Montpellier (Chemo Group): Argentine pharmaceutical laboratory specializing in hospital-use specialty products, hormonal therapies, and other ethical pharmaceuticals — therapeutic mix and channel structure directly overlap with KILAB's product portfolio.
• Gador: Established Argentine pharma company producing branded generics and specialty therapeutics for the hospital channel. Operates a similar GMP manufacturing model targeting Argentine healthcare institutions, comparable to KILAB.
• Laboratorios Richmond: Argentine pharmaceutical manufacturer strong in hospital and specialty generics, notably active in biotechnology and contract manufacturing. Closely comparable domestic pharma with hospital channel and CDMO exposure mirroring KILAB's structure.
• Laboratorios Raymos: Argentine pharmaceutical company with strong third-party manufacturing (tercerismo) and quality control service offerings. Directly comparable as a domestic CDMO competitor pursuing the same flexible manufacturing revenue model.

Broad incumbents

• Apotex: Large global generic pharmaceutical manufacturer with a broad antibiotic and injectable portfolio sold to hospitals worldwide. Comparable as a generic antibiotic competitor in the same cephalosporin/beta-lactam categories KILAB manufactures.
• Teva Pharmaceutical Industries: World's largest generic medicines company with deep antibiotic and injectable portfolios serving global hospital markets. Comparable as a broad incumbent competing in the same generic antibiotic categories that anchor KILAB's product range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/kilablaboratorio
• LinkedInlinkedin.com/company/kilab

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about kilab